Skip to main content
Erschienen in: BMC Women's Health 1/2024

Open Access 01.12.2024 | Research

Association of tet methylcytosine dioxygenase 2 and 5-hydroxymethylcytosine in endometrioid adenocarcinoma and its clinical significance

verfasst von: Lei Kuang, Jingbo Zhang, Yanyu Li, Qing Wang, Jianwei Liu, Bei Zhang

Erschienen in: BMC Women's Health | Ausgabe 1/2024

Abstract

Background

Aberrant DNA methylation is a vital molecular alteration commonly detected in type I endometrial cancers (EC), and tet methylcytosine dioxygenase 2 (TET2) and 5-hydroxymethylcytosine (5hmC) play significant roles in DNA demethylation. However, little is known about the function and correlation of TET2 and 5hmC co-expressed in EC. This study intended to investigate the clinical significance of TET2 and 5hmC in EC.

Methods

The levels of TET2 and 5hmC were detected in 326 endometrial tissues by immumohistochemistry, and the correlation of their level was detected by Pearson analysis. The association between the levels of TET2 and 5hmC and clinicopathologic characteristics was analyzed. Prognostic value of TET2 and 5hmC was explored by Kaplan–Meier analysis. The Cox proportional hazard regression model was used for univariate and multivariate analyses.

Results

Based on the analysis results, TET2 protein level was positively correlated with 5hmC level in EC tissues (r = 0.801, P < 0.001). TET2+5hmC+ (high TET2 and high 5hmC) association was significantly associated with well differentiation, myometrial invasion, negative lymph node metastasis, and tumor stage in EC. Association of TET2 and 5hmC was confirmed as a prognostic factor (HR = 2.843, 95%CI = 1.226–3.605, P = 0.007) for EC patients, and EC patients with TET25hmC level had poor overall survival.

Conclusions

In summary, the association of TET2 and 5hmC was downregulated in EC tissues, and may be a potential poor prognostic indicator for EC patients. Combined detection of TET2 and 5hmC may be valuable for the diagnosis and prognosis of EC.
Hinweise
Lei Kuang and Jingbo Zhang contributed equally to this work as Co-first author.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
EC
Endometrial cancer
TET2
Tet methylcytosine dioxygenase 2
5hmC
5-Hydroxymethylcytosine
5mC
5-Methylcytosine

Introduction

Endometrial cancer (EC) is one of the most prevalent gynecological cancers, which accounts for 20%–30% of female genital malignancies and 7% of female systemic malignancies [1]. In recent years, the incidence of EC in China has increased year by year, and the age of onset is getting younger and younger [2]. Although early diagnosis results in a good overall prognosis for most EC patients, 15%-20% of EC patients still experience postoperative recurrence and tumor metastasis [3]. In addition, although the treatment plan of surgery combined with radiotherapy and chemotherapy can achieve good therapeutic effect, the risk of postoperative reproductive function loss and recurrence brought about by conservative treatment still poses a serious threat to the physical and mental health of patients with EC. The prognosis of advanced or recurrent EC is poor, and the 5-year survival rate is significantly reduced, about 17%-30% [4, 5]. Accordingly, it is of utmost importance to investigate the pathogenesis of EC, find new therapeutic targets, and explore effective prognostic indicators.
The development of EC is a multistep process involving many molecular biological changes. EC has been shown to be a complex disease driven by abnormal genetic and epigenetic alterations, as well as environmental factors. DNA methylation (generating 5-methylcytosine [5mC]) and hydroxymethylation (generating 5-hydroxymethylcytosine [5hmC]) are significant epigenetic modifications that are frequently found in cancer. Aberrant DNA methylation is a significant biochemical change frequently detected in EC. Ten-eleven translocation (TET) protein family, including TET1, 2 and 3, belongs to the α-ketoglutarate and ferrous ion-dependent dioxygenase family. All three proteins play a vital role in DNA demethylation [6], and can catalyze 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5hmC) [7]. The dynamic balance of 5-mC and 5hmC is essential for epigenetic stability, and is involved in the development of multiple solid tumors as a common epigenetic modification [8, 9]. The TET2 gene, which is found in chromosome 4q24 and has 11 exons with a total length of 150 kb, encoding TET2 protein, and TET2 gene, which is produced after a gene fission event during vertebrate evolution, lacks the CpG DNA binding CXXC domain which exists in TET1 and TET3 [10]. Depletion of TET2 can cause DNA hypermethylation at up to 25% of active transcriptional enhancer elements in human hematopoietic cells [11]. Depletion of TET2 in mouse embryonic stem cells leads to significant loss of 5hmC at enhancers, along with an increase in enhancer hypermethylation and a decrease in enhancer activity [12]. Abnormal level of TET2 and 5hmC has been demonstrated in various cancers, such as leukemia [13, 14], breast cancer [15], colorectal cancer [16, 17], and melanoma [18]. However, the role of TET2 and 5hmC two in EC is poorly understood.
In another study, we compared TET2 level between different histopathological samples (Endometrioid endometrial adenocarcinoma, Serous endometrial adenocarcinoma, Mixed serous and endometrioid). The results showed that the level of TET2 was significantly different among different histopathological samples, and it was significantly over-expressed in endometrioid endometrial adenocarcinoma [19]. Endometrioid endometrial adenocarcinoma accounts for 80–90% of the pathological types of EC. In this study, the level of TET2 and 5hmC in EC and normal proliferative endometrium was evaluated by immunohistochemistry. Further, we analyzed the relationship between TET2 and 5hmC as well as with clinical characteristics and overall survival of EC patients. This study intended to examine the clinical significance of TET2 and 5hmC in EC.

Methods

Tissue samples and clinical data

This was a retrospective study. Endometrial samples were collected from 326 patients who had received surgery in the Department of Gynecological Oncology, Xuzhou Central Hospital (Xuzhou, China) from October 2012 and June 2014. This study included 62 normal endometrial (NE) tissues and 264 EC tissues. The NE tissues were extracted from women having hysterectomy for conditions such as uterine prolapse or fibroids. Clinical information was collected from medical record, including age, menopausal status, differentiation, myometrial invasion, lymph node metastasis, and clinical stage. Tumor staging of the EC samples was determined following the International Federation of Gynecology and Obstetrics (FIGO) criteria [20], and histological grade and type following World Health Organization classification [21].
Inclusion criteria were as follows: (1) a diagnosis of endometrial adenocarcinoma or normal proliferative endometrial tissue confirmed by pathological examination; (2) complete clinical information; and (3) outpatient or telephone follow-up after treatment. Exclusion criteria were as follows: (1) preoperative treatment with radiotherapy, chemotherapy, or targeted drugs; (2) presence of other systemic malignancies, or metastatic carcinoma from other organ tumors of the reproductive system (including multiple primary cancer); (3) a history of out-of-hospital treatment.
All 264 patients with EC received outpatient or telephone follow-up. The beginning of treatment was the start of follow-up, and June 30, 2019 was the end of follow-up end. Patients who died from an accident or other unrelated illness were reported as censored events. This study was approved by the Ethics Committee of Xuzhou Central Hospital and each patient signed the informed consent.

Immunohistochemistry (IHC) analysis

Paraffin-embedded tissue blocks were serially cut at a thickness of 4 μm. The obtained sections were treated with 3% hydrogen peroxide, and antigen retrieval was performed in a high-temperature environment. Next the sections were incubated at 4 °C overnight with primary antibodies TET2 (ab94580, Abcam, UK) and 5hmC (ab214728, Abcam, UK) at 1:200 dilution, and then with peroxidase-labeled secondary antibody (Sigma–Aldrich) for 30 min at 37 °C. 3,3′-Diaminobenzidine (Affinity, ZLI-9018) substrate was responsible for color development. Instead of the primary antibody, phosphate buffered saline (Sigma–Aldrich) was utilized as a negative control. A double-blind analysis of the sections was performed by two experienced pathologists. TET2 positivity was visible as yellow–brown granules in the nucleus and cytoplasm, and 5hmC positive staining was visible as a brownish yellow color in the nucleus. The intensity of IHC staining for cells in endometrial tissue was rated as 0 (negative), 1 (weakly positive), 2 (moderately positive), and 3 (strongly positive). The final staining score of tissue = (1 × percentage of weakly positive cells + 2 × percentage of moderately positive cells + 3 × percentage of strongly positive cells) × 100, and the final staining score ranged from 0 to 300. Using X⁃Tile software, the level of TET2 and 5hmC was classified into “low or no” level and “high” level based on the survival prognosis of EC patients. The cut-off value for TET2 and 5hmC was selected as 130. Tissues with staining score 0–130 were deemed as “low or no level”, which is denoted by “ ”, while 131–300 was regarded as “high level”, which is denoted by “ +”.

Statistical analysis

Statistical analysis was carried out using SPSS 22.0 statistical software (SPSS Inc., USA). The association between clinicopathologic characteristics and TET2/5hmC level was examined using chi-square test. Pearson correlation analysis was conducted to find the link between TET2 and 5hmC in EC tissues. The Kaplan–Meier method was utilized for the survival analysis, and the log-rank test for comparison of differences in the overall survival rate. Both univariate and multivariate analyses were conducted using the Cox proportional hazard regression model. Statistical significance was defined as P < 0.05.

Results

Level of TET2 and 5hmC in endometrial tissues

As shown in Fig. 1A–B, TET2-positive staining appeared as yellow–brown granules in the nucleus and cytoplasm, while 5hmC-positive staining as brownish yellow in the nucleus. According to the staining score, endometrial tissues were classified as high TET2 and high 5hmC (TET2+5hmC+), high TET2 and low 5hmC (TET2+5hmC), low TET2 and high 5hmC (TET25hmC+), and low TET2 and low 5hmC (TET25hmC). The rate of TET2+5hmC+, TET2+5hmC, TET25hmC+, and TET25hmC in EC tissues were 51.52%, 0.76%, 7.95%, and 38.26% respectively. EC tissues had a lower rate of TET2+5hmC+ than that in NE tissues (51.52% vs. 79.03%), and TET25hmC was not detected in normal endometrium (Table 1).
Table 1
Association of TET2 and 5hmC in endometrial tissues
Characteristic
n
TET2
 + 
 + 
-
-
χ2
P
5hmC
 + 
-
 + 
-
Normal proliferative endometrium
62
 
49 (79.03)
5 (8.06)
8 (12.90)
0 (0.00)
36.793
< 0.001*
Endometrioid endometrial adenocarcinoma
264
 
136 (51.52)
6 (0.76)
21 (7.95)
101 (38.26)
  
 + : high level, -: Low or no level, *P <0.05

Correlation of 5hmC and TET2 in EC tissues

The relationship between TET2 and 5hmC was discovered using a Pearson correlation analysis. As shown in Fig. 2, TET2 level was positively correlated with 5hmC (r = 0.801 and P < 0.001).

Relationship between clinicopathologic characteristics and TET2/5hmC association in EC

The relationship between TET2/5hmC association and clinicopathologic characteristics was explored in 264 EC patients (Table 2). The results showed that TET2/5hmC association was significantly associated with differentiation (χ2 = 82.249, P < 0.001), myometrial invasion (χ2 = 44.060, P < 0.001), lymph node metastasis (χ2 = 15.231, P = 0.002), and FIGO stage (χ2 = 38.769, P < 0.001). However, there was no correlation between TET2/5hmC association and age or menopausal status (P > 0.05).
Table 2
Association of TET2 and 5hmC and clinicopathological characteristics of EC patients
Characteristics
n
TET2
 + 
 + 
-
-
χ2
P
5hmC
 + 
-
 + 
-
Total
264
 
136 (51.52)
6 (0.76)
21 (7.95)
101 (38.26)
  
Age (year)
      
4.857
0.183
 ≥ 45
225
 
121 (53.78)
4 (1.78)
16 (7.11)
84 (37.33)
  
 < 45
39
 
15 (38.46)
2 (5.13)
5 (12.82)
17 (43.59)
  
Menopausal status
      
2.077
0.557
 Pre-menopause
93
 
52 (55.91)
3 (3.23)
6 (6.45)
32 (34.41)
  
 Post-menopause
171
 
84 (49.12)
3 (1.75)
15 (8.77)
69 (40.35)
  
Differentiation
      
82.249
< 0.001*
 Well
166
 
119 (71.69)
3 (3.61)
12 (7.23)
32 (19.28)
  
 Moderate
37
 
10 (27.03)
0 (0.00)
3 (8.11)
24 (64.86)
  
 Poor
61
 
7 (11.48)
3 (4.92)
6 (9.84)
45 (73.77)
  
Myometrial invasion
      
44.060
< 0.001*
 < 1/2
174
 
112 (64.38)
5 (2.87)
15 (8.62)
42 (24.14)
  
 ≥ 1/2
90
 
24 (26.67)
1 (1.11)
6 (6.67)
59 (65.56)
  
Lymph node metastasis
      
15.231
0.002*
 Negative
240
 
132 (55.00)
4 (1.67)
18 (7.50)
86 (35.83)
  
 Positive
24
 
4 (16.67)
2 (8.33)
3 (12.50)
15 (62.50)
  
FIGO Stage
      
38.769
< 0.001*
 I
195
 
121 (62.05)
3 (1.54)
15 (7.69)
56 (28.72)
  
 II
24
 
6 (25.00)
2 (8.33)
2 (8.33)
14 (58.33)
  
 III
45
 
9 (20.00)
1 (2.22)
4 (8.89)
31 (68.89)
  
*P <0.05

Correlation of TET2/5hmC association with prognosis of EC patients

Prognostic variables for EC patients were identified using both univariate and multivariate analysis. Univariate analysis showed that TET2/5hmC association (P < 0.001), differentiation (P = 0.036), lymph node metastasis (P = 0.015), and FIGO stage (P = 0.006) were significantly related to overall survival of EC patients. Multivariate analysis further demonstrated TET2/5hmC association (HR: 2.843; 95%CI: 1.226–3.605; P = 0.007), lymph node metastasis (HR: 5.241; 95%CI: 1.169–13.856; P = 0.037), and FIGO stage (HR: 3.979; 95%CI: 2.153–6.780; P = 0.023) were independent prognostic factors for EC patients (Table 3).
Table 3
Univariate and multivariate analyses of the prognostic factors for overall survival in EC
 
Univariate analysis
Multivariate analysis
 
HR
P value
95%CI
HR
P value
95%CI
TET2 and 5hmC level
 T+5+ vs T+5vs T5+ vs T5
3.035
< 0.001*
1.751–5.259
2.843
0.007*
1.226–3.605
Age (year)
 
0.989
0.986
0.308–3.181
   
Menopausal status
 Pre-vs Post-menopause
1.056
0.835
0.634–1.759
   
Differentiation
 Well vs Moderate vs Poor
1.812
0.036*
1.040–3.157
   
Myometrial invasion
 < 1/2 vs ≥ 1/2
0.955
0.868
0.551–1.653
   
Lymph node metastasis
 Negative vs Positive
5.828
0.015*
1.329–14.615
5.241
0.037*
1.169–13.856
FIGO Stage
 I vs II vs III
4.261
0.006*
2.347–7.154
3.979
0.023*
2.153–6.780
HR Hazard ratio, CI Confidence interval
*P < 0.05
Kaplan–Meier survival curve demonstrated that the overall survival rate of TET2 + 5hmC + EC patients was higher than that of TET2 + 5hmC + /TET2 + 5HMC-EC patients, and the overall survival time of TET2 + 5hmC + EC patients in FIGO stage I was significantly longer. Compared with TET2 + 5hmC + and TET2 + 5hmC + /TET2 + 5hmC-, patients with TET2-5HMC-EC had significantly lower overall survival rates and the lowest overall survival rates at all FIGO stages (Fig. 3). Hazard ratios were further calculated for disease stage, and the results showed an association between TET25hmC level and poor overall survival in FIGO Stage I (χ2 = 17.559, P < 0.001) and Stage III (χ2 = 6.590, P = 0.037) patients. There was no significant difference between TET25hmC level and adverse overall survival in patients with Stage II (χ2 = 1.750, P = 0.417) (Fig. 3B-D).

Discussion

DNA methylation, an important epigenetic modification, controls gene expression and maintains genome structure [22]. Abnormal DNA methylation is frequently occurs in the promoter region of transcription factors. Tumorigenesis typically results from either hyper-or hypomethylation. DNA hypermethylation in tumor suppressor motifs leads to transcription inhibition and downregulation of tumor suppressor genes. DNA hypomethylation activates proto-oncogenes and affects chromosome stability [23]. DNA methylation is a characterization and reflection of early molecular variations in human tumors, indicating that the studies on DNA methylation is anticipated to provide novel methods for early identification and prevention of tumors.
Previous studies have found that both the TET protein family and 5hmC play important roles in tumor development and progression [24]. TET2 expression was lower in normal tissues than that in some epithelial neoplasms, such as breast adenocarcinoma and gastric cancer [25, 26]. However, Yang et al. confirmed that TET2 mRNA and protein level in hepatic cancerous tissues were both raised compared with normal hepatic tissues [27].
5-mC can be hydroxylated to 5hmC under the catalysis of TET proteins. 5hmC plays a key role in neural development, and abnormal 5hmC level was found in some neurological diseases such as Alzheimer's disease [28]. Mounting evidence has demonstrated that 5hmC is involved in the pathogenesis of various tumors. 5hmC level in some malignant tumors, like lung cancer, liver cancer, breast cancer and melanoma, was significantly decreased compared with normal tissues, whereas its level was increased in benign uterine leiomyoma [2932]. In another study, we compared the differential level of TET2 between normal endometrial tissue and endometrial cancer tissue was observed using the endometrial cancer data in TCGA database [19]. The results showed that the level of TET2 was significantly different among different histopathological samples, and it was significantly over-expressed in endometrioid endometrial adenocarcinoma.
This study detected the association of 5hmC and TET2 in EC tissues. In comparison to normal endometrial tissues, EC tissues showed a lower rate of TET2+5hmC+ association (51.52% vs. 79.03%) and a significantly higher rate of TET2/5hmC association (38.26% vs. 0.00%). Furthermore, TET2 level level was positively associated with 5hmC level in EC tissues, which was basically consistent with the result of Ciesielski et al. [33]. The association of TET2 and 5hmC was related to well differentiation, myometrial invasion, FIGO stage, and negative lymph node metastasis. These results suggested that high level of TET2 and 5hmC may inhibit EC progression.
Wang et al. stated that TET2 mutation was an independent prognostic factor for acute myeloid leukemia [34]. Downregulation of TET2 mRNA in prostate cancer was found to be strongly associated with reduced survival [35]. Similarly, 5hmC loss was linked to poor overall survival in ovarian cancer and pediatric central nervous system tumor [36, 37]. In this study, univariate analysis showed that the association of TET2 and 5hmC, differentiation, FIGO stage, and lymph node status were correlated with survival of EC patients. Further multivariate analysis revealed the association of TET2 and 5hmC, FIGO stage, and lymph node metastasis were independent factors affecting EC prognosis. Additionally, Kaplan–Meier survival curve proved that the association of TET25hmC predicted poor overall survival of EC patients. Collectively, association of TET2 and 5hmC is closely related to the prognosis of EC patients.

Limitations

Our study suggests that abnormal level of TET2 and 5hmC may be a potential diagnostic and therapeutic target for EC. Thus the simultaneous detection of TET2 and 5hmC in clinical practice is of great significance for diagnosing and predicting the prognosis of EC. However, this study also has the limitation of a small sample size, which limits their clinical development and application. Therefore, our conclusion needs to be further validated by large-scale, multi-stage, and multi-center clinical trials.

Conclusion

Our study suggests that abnormal level of TET2 and 5hmC may be a potential diagnostic and therapeutic target for EC. Thus the simultaneous detection of TET2 and 5hmC in clinical practice is of great significance for diagnosing and predicting the prognosis of EC. However, this study also has the limitation of a small sample size, which limits their clinical development and application. Therefore, our conclusion needs to be further validated by large-scale, multi-stage, and multi-center clinical trials.

Acknowledgements

Not applicable.

Declarations

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Xuzhou Central Hospital ethics committee (XZXY-LJ-20210302–021). And all patients signed the informed consent.
Not applicable.

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Ha Thout L, Wang Y, Wang Q, Vergalasova I, Lee LJ. A multi-institutional analysis of adjuvant chemotherapy and radiation sequence in women with Stage IIIC endometrial cancer. Int J Radiat Oncol Biol Phys. 2021;110:1423–31.CrossRef Ha Thout L, Wang Y, Wang Q, Vergalasova I, Lee LJ. A multi-institutional analysis of adjuvant chemotherapy and radiation sequence in women with Stage IIIC endometrial cancer. Int J Radiat Oncol Biol Phys. 2021;110:1423–31.CrossRef
2.
Zurück zum Zitat Joannie LT, Jacques F, Freddie B, Ahmedin J. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2018;110:4. Joannie LT, Jacques F, Freddie B, Ahmedin J. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2018;110:4.
3.
Zurück zum Zitat Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncology. 2012;13:e353–61.CrossRefPubMed Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncology. 2012;13:e353–61.CrossRefPubMed
4.
Zurück zum Zitat Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer Lacent. 2016;387:1094–108. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer Lacent. 2016;387:1094–108.
5.
Zurück zum Zitat JIn W, Wang L, Liu Y, Liu A. Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer. Chin J Obstet Gynecol. 2018;053:823–30. JIn W, Wang L, Liu Y, Liu A. Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer. Chin J Obstet Gynecol. 2018;053:823–30.
6.
Zurück zum Zitat Veron N. Tet proteins: on track towards DNA demethylation? Biomol Concepts. 2012;3:395–402.CrossRefPubMed Veron N. Tet proteins: on track towards DNA demethylation? Biomol Concepts. 2012;3:395–402.CrossRefPubMed
7.
Zurück zum Zitat Lio C, Shukla V, Samaniego-Castruita D, González-Avalos E, Chakraborty A, Yue X, et al. TET enzymes augment activation-induced deaminase (AID) expression via 5-hydroxymethylcytosine modifications at the Aicda superenhancer. Science Immunology. 2019;4:eaau7523.CrossRefPubMedPubMedCentral Lio C, Shukla V, Samaniego-Castruita D, González-Avalos E, Chakraborty A, Yue X, et al. TET enzymes augment activation-induced deaminase (AID) expression via 5-hydroxymethylcytosine modifications at the Aicda superenhancer. Science Immunology. 2019;4:eaau7523.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Madrid A, Chopra P, Alisch RS. Species-specific 5 mC and 5 hmC genomic landscapes indicate epigenetic contribution to human brain evolution. Front Mol Neurosci. 2018;11:39.CrossRefPubMedPubMedCentral Madrid A, Chopra P, Alisch RS. Species-specific 5 mC and 5 hmC genomic landscapes indicate epigenetic contribution to human brain evolution. Front Mol Neurosci. 2018;11:39.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13:484–92.CrossRefPubMed Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13:484–92.CrossRefPubMed
10.
Zurück zum Zitat Ko M, An J, Bandukwala HS, Chavez L, Aijö T, Pastor WA, et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature. 2013;497:122–6.ADSCrossRefPubMedPubMedCentral Ko M, An J, Bandukwala HS, Chavez L, Aijö T, Pastor WA, et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature. 2013;497:122–6.ADSCrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Helin K. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev. 2015;29:910–22.CrossRefPubMedPubMedCentral Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Helin K. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev. 2015;29:910–22.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Hon Gary C, Song CX, Du T, Jin F, Selvaraj S, Lee AhY, et al. 5mC Oxidation by Tet2 Modulates Enhancer Activity and Timing of Transcriptome Reprogramming during Differentiation. Mol Cell. 2014;56:286–97.CrossRefPubMedPubMedCentral Hon Gary C, Song CX, Du T, Jin F, Selvaraj S, Lee AhY, et al. 5mC Oxidation by Tet2 Modulates Enhancer Activity and Timing of Transcriptome Reprogramming during Differentiation. Mol Cell. 2014;56:286–97.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Zhang P, Weng WW, Chen P, Zhang Y, Ruan JF, Ba DD, et al. Low expression of TET2 gene in pediatric acute lymphoblastic leukemia is associated with poor clinical outcome. Int J Lab Hematol. 2019;41:702–9.CrossRefPubMed Zhang P, Weng WW, Chen P, Zhang Y, Ruan JF, Ba DD, et al. Low expression of TET2 gene in pediatric acute lymphoblastic leukemia is associated with poor clinical outcome. Int J Lab Hematol. 2019;41:702–9.CrossRefPubMed
14.
Zurück zum Zitat Kroeze LI, Aslanyan MG, van Rooij A, Koorenhof-Scheele TN, Massop M, Carell T, et al. Characterization of acute myeloid leukemia based on levels of global hydroxymethylation. Blood. 2014;124:1110–8.CrossRefPubMed Kroeze LI, Aslanyan MG, van Rooij A, Koorenhof-Scheele TN, Massop M, Carell T, et al. Characterization of acute myeloid leukemia based on levels of global hydroxymethylation. Blood. 2014;124:1110–8.CrossRefPubMed
15.
Zurück zum Zitat Gu P, Luo X, Zhang H, Tan L, Chen H, Kong L, et al. Relationship between TET2 Mutations and Expression of 5hmC in Breast Cancer Tissues. Chinese J Clin Med. 2015;22:1–4. Gu P, Luo X, Zhang H, Tan L, Chen H, Kong L, et al. Relationship between TET2 Mutations and Expression of 5hmC in Breast Cancer Tissues. Chinese J Clin Med. 2015;22:1–4.
16.
Zurück zum Zitat Huang Y, Wang G, Liang Z, Yang Y, Cui L, Liu C-Y. Loss of nuclear localization of TET2 in colorectal cancer. Clin Epigenetics. 2016;8:1–3.CrossRef Huang Y, Wang G, Liang Z, Yang Y, Cui L, Liu C-Y. Loss of nuclear localization of TET2 in colorectal cancer. Clin Epigenetics. 2016;8:1–3.CrossRef
17.
Zurück zum Zitat Dang Y, Hu D, Xu J, Li C, Tang Y, Yang Z, et al. Comprehensive analysis of 5-hydroxymethylcytosine in zw10 kinetochore protein as a promising biomarker for screening and diagnosis of early colorectal cancer. Clin Transl Med. 2020;10:e125.CrossRefPubMedPubMedCentral Dang Y, Hu D, Xu J, Li C, Tang Y, Yang Z, et al. Comprehensive analysis of 5-hydroxymethylcytosine in zw10 kinetochore protein as a promising biomarker for screening and diagnosis of early colorectal cancer. Clin Transl Med. 2020;10:e125.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Pavlova O, Fraitag S, Hohl D. 5-Hydroxymethylcytosine Expression in Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma. J Investig Dermatol. 2016;136:2453–61.CrossRefPubMed Pavlova O, Fraitag S, Hohl D. 5-Hydroxymethylcytosine Expression in Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma. J Investig Dermatol. 2016;136:2453–61.CrossRefPubMed
19.
Zurück zum Zitat Zhang J, Kuang L, Li Y, Wang Q, Xu H, Liu J, et al. Metformin regulates TET2 expression to inhibit endometrial carcinoma proliferation: a new mechanism. Front Oncol. 2022;12:856707.CrossRefPubMedPubMedCentral Zhang J, Kuang L, Li Y, Wang Q, Xu H, Liu J, et al. Metformin regulates TET2 expression to inhibit endometrial carcinoma proliferation: a new mechanism. Front Oncol. 2022;12:856707.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105:109.CrossRefPubMed Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105:109.CrossRefPubMed
21.
Zurück zum Zitat Silverberg SG, Mutter GL, Kurman RJ, Kubik-Huch RA, Nogales F, Tavassoli FA. Tumors of the uterine corpus: epithelial tumors and related lesions//Tavassoli FA, Stratton MR. WHO Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon: IARC Press; 2003. p. 221–232. Silverberg SG, Mutter GL, Kurman RJ, Kubik-Huch RA, Nogales F, Tavassoli FA. Tumors of the uterine corpus: epithelial tumors and related lesions//Tavassoli FA, Stratton MR. WHO Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon: IARC Press; 2003. p. 221–232.
22.
Zurück zum Zitat Ding W, Chen G, Shi T. Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis. Epigenetics. 2019;14:67–80.CrossRefPubMedPubMedCentral Ding W, Chen G, Shi T. Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis. Epigenetics. 2019;14:67–80.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Yang X, Gao L, Zhang S. Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns. Brief Bioinform. 2017;18:761–73.PubMed Yang X, Gao L, Zhang S. Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns. Brief Bioinform. 2017;18:761–73.PubMed
24.
Zurück zum Zitat Gal-Yam EN, Saito Y, Egger G, Jones PA. Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med. 2008;59:267–80.CrossRefPubMed Gal-Yam EN, Saito Y, Egger G, Jones PA. Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med. 2008;59:267–80.CrossRefPubMed
26.
Zurück zum Zitat Deng W, Wang J, Zhang J, Cai J, Bai Z, Zhang Z. TET2 regulates LncRNA-ANRIL expression and inhibits the growth of human gastric cancer cells. IUBMB Life. 2016;68:355–64.CrossRefPubMed Deng W, Wang J, Zhang J, Cai J, Bai Z, Zhang Z. TET2 regulates LncRNA-ANRIL expression and inhibits the growth of human gastric cancer cells. IUBMB Life. 2016;68:355–64.CrossRefPubMed
27.
Zurück zum Zitat Yang G, Xiang Z, Wang M, Wu A. The TET2/E-cadherin/β-catenin regulatory loop confers growth and invasion in hepatocellular carcinoma cells. Exp Cell Res. 2018;363:218–26.CrossRefPubMed Yang G, Xiang Z, Wang M, Wu A. The TET2/E-cadherin/β-catenin regulatory loop confers growth and invasion in hepatocellular carcinoma cells. Exp Cell Res. 2018;363:218–26.CrossRefPubMed
28.
Zurück zum Zitat Zhang Y, Zhang Z, Li L, Xu K, Ma Z, Chow H-M, et al. Selective loss of 5hmC promotes neurodegeneration in the mouse model of Alzheimer's disease. FASEB J. 2020;34:16364–82.CrossRefPubMed Zhang Y, Zhang Z, Li L, Xu K, Ma Z, Chow H-M, et al. Selective loss of 5hmC promotes neurodegeneration in the mouse model of Alzheimer's disease. FASEB J. 2020;34:16364–82.CrossRefPubMed
29.
Zurück zum Zitat Jin SG, Jiang Y, Qiu R, Rauch TA, Pfeifer GP. 5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers but Its Levels Do Not Correlate with IDH1 Mutations. Can Res. 2011;71:7360–5.CrossRef Jin SG, Jiang Y, Qiu R, Rauch TA, Pfeifer GP. 5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers but Its Levels Do Not Correlate with IDH1 Mutations. Can Res. 2011;71:7360–5.CrossRef
30.
Zurück zum Zitat Antonia N, Yin P, Masanori O, Diana M, Moravek MB, Coon JS, et al. 5-Hydroxymethylcytosine promotes proliferation of human uterine leiomyoma: a biological link to a new epigenetic modification in benign tumors. J Clin Endocrinol Metab. 2014;99:2437–45.CrossRef Antonia N, Yin P, Masanori O, Diana M, Moravek MB, Coon JS, et al. 5-Hydroxymethylcytosine promotes proliferation of human uterine leiomyoma: a biological link to a new epigenetic modification in benign tumors. J Clin Endocrinol Metab. 2014;99:2437–45.CrossRef
31.
Zurück zum Zitat Wang Z, Du M, Yuan Q, Guo Y, Hutchinson JN, Su L, et al. Epigenomic analysis of 5-hydroxymethylcytosine (5hmC) reveals novel DNA methylation markers for lung cancers. Neoplasia. 2020;22:154–61.CrossRefPubMedPubMedCentral Wang Z, Du M, Yuan Q, Guo Y, Hutchinson JN, Su L, et al. Epigenomic analysis of 5-hydroxymethylcytosine (5hmC) reveals novel DNA methylation markers for lung cancers. Neoplasia. 2020;22:154–61.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Bao B, Teslow EA, Mitrea C, Boerner JL, Bollig-Fischer A. Role of TET1 and 5hmC in an obesity-linked pathway driving cancer stem cells in triple-negative breast cancer. Mol Cancer Res. 2020;18:1803–14.CrossRefPubMedPubMedCentral Bao B, Teslow EA, Mitrea C, Boerner JL, Bollig-Fischer A. Role of TET1 and 5hmC in an obesity-linked pathway driving cancer stem cells in triple-negative breast cancer. Mol Cancer Res. 2020;18:1803–14.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Ciesielski P, Jozwiak P, Wojcik-Krowiranda K, Forma E, Cwonda L, Szczepaniec S, et al. Differential expression of ten-eleven translocation genes in endometrial cancers. Tumour Biol. 2017;39:1010428317695017.CrossRefPubMed Ciesielski P, Jozwiak P, Wojcik-Krowiranda K, Forma E, Cwonda L, Szczepaniec S, et al. Differential expression of ten-eleven translocation genes in endometrial cancers. Tumour Biol. 2017;39:1010428317695017.CrossRefPubMed
34.
Zurück zum Zitat Wang R, Chen C, Jing Y, Qin J, Li Y, Chen G, et al. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique. Cancer Med. 2020;9:8457–67.CrossRefPubMedPubMedCentral Wang R, Chen C, Jing Y, Qin J, Li Y, Chen G, et al. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique. Cancer Med. 2020;9:8457–67.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Nickerson ML, Das S, Im KM, Turan S, Berndt SI, Li H, et al. TET2 binds the androgen receptor and loss is associated with prostate cancer. Oncogene. 2017;36:2172–83.CrossRefPubMed Nickerson ML, Das S, Im KM, Turan S, Berndt SI, Li H, et al. TET2 binds the androgen receptor and loss is associated with prostate cancer. Oncogene. 2017;36:2172–83.CrossRefPubMed
36.
Zurück zum Zitat Azizgolshani N, Petersen CL, Chen Y, Levy JJ, Salas LA, Perreard L, et al. DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor. Clin Epigenetics. 2021;13:176.CrossRefPubMedPubMedCentral Azizgolshani N, Petersen CL, Chen Y, Levy JJ, Salas LA, Perreard L, et al. DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor. Clin Epigenetics. 2021;13:176.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Tucker DW, Getchell CR, Mccarthy ET, Ohman AW, Sasamoto N, Xu S, et al. Epigenetic reprogramming strategies to reverse global loss of 5-hydroxymethylcytosine, a prognostic factor for poor survival in high-grade serous ovarian cancer. Clin Cancer Res. 2017;24:1389–401.CrossRefPubMedPubMedCentral Tucker DW, Getchell CR, Mccarthy ET, Ohman AW, Sasamoto N, Xu S, et al. Epigenetic reprogramming strategies to reverse global loss of 5-hydroxymethylcytosine, a prognostic factor for poor survival in high-grade serous ovarian cancer. Clin Cancer Res. 2017;24:1389–401.CrossRefPubMedPubMedCentral
Metadaten
Titel
Association of tet methylcytosine dioxygenase 2 and 5-hydroxymethylcytosine in endometrioid adenocarcinoma and its clinical significance
verfasst von
Lei Kuang
Jingbo Zhang
Yanyu Li
Qing Wang
Jianwei Liu
Bei Zhang
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
BMC Women's Health / Ausgabe 1/2024
Elektronische ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-024-03021-2

Weitere Artikel der Ausgabe 1/2024

BMC Women's Health 1/2024 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.